Citius Oncology Reports Positive Phase 1 LYMPHIR Data in Gynecologic Cancers
Summary
Citius Pharmaceuticals' subsidiary, Citius Oncology, reported positive Phase 1 clinical data for LYMPHIR in gynecologic cancers, showing durable responses and good tolerability, which is a significant development for the financially challenged company.
Key Events
-
Positive Phase 1 Clinical Data
Citius Oncology presented encouraging Phase 1 data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at ASCO.
-
Durable Responses Observed
The study showed a 24% overall response rate and a 33% objective response rate in endometrial cancer patients previously treated with checkpoint inhibitors.
-
Prolonged Progression-Free Survival
A median progression-free survival of 20.5 months was observed among patients achieving clinical benefit.
-
Manageable Safety Profile
The combination therapy demonstrated a manageable tolerability profile with no new safety signals or severe immune-related adverse events.
Analysis
Citius Oncology, a subsidiary of Citius Pharmaceuticals, announced encouraging Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies. The data, presented at ASCO, showed durable responses and a manageable safety profile in heavily pre-treated patients, including a 33% objective response rate in endometrial cancer patients previously treated with checkpoint inhibitors. This positive clinical update is critical for Citius Pharmaceuticals, especially following its recent "going concern" warning, as it provides a potential path for future value creation and strengthens the case for ongoing financing.
At the time of this filing, CTXR was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.48 to $2.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.